EscopeTech Secures Hundreds of Millions in Series A+ Funding to Advance Computational Medicine and Expand Cardiocerebral Imaging Solutions

Recently, ESCOPE announced the completion ofHundreds of millions of yuan in Series A+ fundingFinancing; all investors participating in this round of financing are well-known institutional and industrial investors, includingCenturium Capital, Rongquan Venture Capital, Tasly Capital, and the investment fund under Shanda Group. The proceeds from this financing round will be used to accelerate the company's parallel R&D of multiple products, clinical trials in China and the United States, and commercialization.

ESCOPE was founded in 2017 by a team of professors, engineers, and entrepreneurs returning from the United States and Europe. Leveraging standardized evidence-based medicine systems and computational medicine paradigms, the company has built a multi-dimensional medical imaging analysis system centered on CT, MRI, DSA, and other medical imaging modalities. This system is underpinned by four core technological modules: high-precision simulation, graphics and image processing, data mining, and deep neural network learning. It enables a comprehensive upgrade in clinical diagnosis from morphological to functional imaging indicators, with the aim of establishing the world’s most professional imaging and data analysis platform for cardiovascular and cerebrovascular diseases.

ESCOPE’s products are positioned in five major areas: coronary (coronary artery analysis), cardiac (cardiac function assessment), cranial (intracranial artery analysis), cerebral (cerebral function assessment), and peripheral (systemic arterial analysis). ESCOPE provides end-to-end solutions covering the entire workflow for cardiovascular and cerebrovascular diseases, from screening, diagnosis, preoperative planning, and intraoperative navigation to postoperative follow-up. ESCOPEPioneering the "Heart-Vessel Integrated" Detection Model, enabling integrated functional assessment from the heart to the coronary arteries. Currently, ESCOPE has developed multiple AI-assisted imaging products for the diagnosis and treatment of cardiovascular and cerebrovascular diseases, among which its first CT-FFR product, Maiying^®Clinical trials in China have been completed, with the NMPA Class III medical device registration certificate expected to be obtained by mid-2022. The FDA certification process and U.S. clinical trials have also been initiated. The product portfolio includes Cardiac Shadow, software for comprehensive cardiac function evaluation; Silhouette, software that relies on DSA imaging to perform morphological and functional analysis of coronary vessels; and Cranial Shadow, software for assessing cerebrovascular physiological function.^®Several other innovative products have also successively entered clinical trial phases.

Leveraging its proprietary automated image processing technology and ultra-efficient, high-precision hemodynamic simulation technology, ESCOPE has achieved breakthrough improvements in computational efficiency and accuracy, resolved industry technical bottlenecks, and reduced computing power requirements. As a result, its products not only demonstrate significantly higher performance than domestic and international counterparts in key clinical metrics such as sensitivity, specificity, and accuracy, but also achieve true end-to-end full automation in practical deployment. From image input to the generation of structured reports, the solution operates entirely offline and locally, ensuring real-time and efficient case detection even under high-volume hospital testing conditions. Furthermore, the local deployment model guarantees the security and compliance of medical data collection and usage, aligning with the growing emphasis on data security by both the state and the public.

For this round of financing,Zhang Chao, Founder of ESCOPEstated, “These renowned investors’ investment in the company and their long-term, multi-faceted support not only serve as an endorsement and recognition of the company’s competitive strength and development prospects, but will also introduce abundant industry resources and professional talent to the company, helping it enhance and refine its corporate governance standards and propel its business to new heights.”

Chen Zhixing, Managing Director of Centurium Capital“It stated: ‘Functional imaging applications for cardiovascular and cerebrovascular diseases, based on the three core technologies of deep learning, machine vision, and high-precision simulation, offer clear clinical value due to their non-invasive nature, convenience, and high accuracy. In the future, the diagnosis and treatment of cardiovascular and cerebrovascular diseases will progressively advance toward precision and personalized medicine, creating broad market prospects for non-invasive functional imaging applications represented by CT-FFR and DSA-FFR. Led by founder Zhang Chao, the ESCOPE team has accumulated profound technical expertise and demonstrated exceptional independent R&D capabilities in the global field of cardiovascular and cerebrovascular functional imaging. Its core products exhibit prominent technical advantages and outstanding clinical outcomes. Furthermore, the company has proactively established a pipeline of innovative products under development with both Chinese and global novelty, highlighting significant internationalization potential. We are confident that the company will become a leading enterprise in innovative functional imaging applications for cardiovascular and cerebrovascular diseases in China and worldwide.’”

Zhao Hui, Managing Partner of Rongquan Venture Capital“Rongquan Venture Capital is dedicated to identifying companies with disruptive technologies in the healthcare sector—technologies that have the potential to reshape the industry landscape. Since the inception of Escope, we have closely monitored its progress, recognizing the company as a global leader in applying hemodynamic simulation and machine vision technologies to medical imaging. The cross-disciplinary integration and innovation of multiple technologies have enabled Escope to build a robust foundational technology platform, yielding remarkable clinical trial results. Meanwhile, Escope demonstrates the capability to rapidly extend its platform technologies across various domains, including cardiac, cerebral, and systemic vascular applications. The company’s technological and product leadership, coupled with its global patent portfolio, highlights significant opportunities for the worldwide deployment of its products. We congratulate Escope on its achievements and look forward to its further success in commercialization.”

Centurium Capital is a leading private equity fund management firm in China, focusing on investment opportunities in the consumer, healthcare, and enterprise services sectors within the Chinese market. It possesses deep industry insights and extensive resources in its areas of focus. Adhering to the philosophy of “investment-driven transformation,” Centurium Capital makes long-term investments in selected companies and entrepreneurs, helping them formulate effective business strategies and improve operational efficiency to drive corporate growth and industry transformation.

Rongquan Venture Capital is a venture capital fund management firm co-founded by senior bankers from Goldman Sachs. Its management team and strategic partners have many years of in-depth experience in healthcare investment and operations, having established a global resource network. By combining forward-looking vision with strong scientific expertise and sophisticated capital operations, the firm has created a multi-win ecosystem that integrates industry and capital. Rongquan Venture Capital focuses on identifying and empowering outstanding early-stage and growth-stage healthcare projects in China and abroad that feature highly disruptive technologies and significant market potential.

Tasly Capital focuses on investing in mature enterprises within the broader health ecosystem and high-growth companies in emerging niche sectors. Founded in 2007, Tasly Capital is an industrial investment platform that has been incubated, developed, and expanded under Tasly Holding Group’s strategic positioning of “industry as the foundation, finance as the tool, and industry-finance interaction.” Its business scope covers equity investment, industrial M&A, asset management, international investment, and commercial factoring. The RMB funds of Tasly Capital are sponsored by Tasly Holding Group, with major investors including multiple government guidance funds, banks, insurance companies, and institutional investors. Its USD funds are capitalized by renowned international investment institutions.

Shanda Group is a global private investment holding company founded in 1999 by Chen Tianqiao, a pioneer of China’s online interactive entertainment industry, and his family. The group primarily invests in two distinct areas: early-stage startups with truly disruptive technologies, and undervalued public companies with significant potential for performance improvement. Shanda Venture Capital’s G.R.A.B. investment strategy focuses on genetics, AI robotics, anti-aging, and brain science. Additionally, to support future innovation, Shanda has invested in a portfolio of active, emerging early-stage venture capital funds.